

Pharma Services Division



NeoGenomics is a leading and global provider of oncology-focused research and clinical trials services, focused on fit-for-purpose biomarker assay development and testing.

Through our rapidly growing Pharma Services division, we offer our clients the ability to leverage our vast expertise in oncology drug development and commercialization, with support spanning from pre-clinical and research discovery through FDA filing, approval, and launch.

We currently operate in 13 global locations, including in the U.S., Switzerland, Singapore, and China, enabling us to serve the world-wide clinical research and companion diagnostic needs of our pharma clients.

Offerings and Services

We offer one of the most comprehensive laboratory services menus available for oncology clinical trials, with core technologies deployed for our clients, including:

- Anatomic Pathology
- Molecular including Next Generation Sequencing
- Multiplexed Immuno-Fluorescence
- Flow Cytometry
- Immunoassays
- FISH & Cytogenetics

Uniquely Positioned for Companion Diagnostics

Companion diagnostics (CDx) are an integral part of oncology treatments and for unlocking the promise of precision medicine. NeoGenomics partners with leading organizations to advance companion tests from development, through clinical trials, and into the market. Our customers can also leverage the vast data of oncology-specific test results that we have amassed and our broad reach with oncologists and pathologists in their CDx programs.

Quick Facts

- Employs more than 120 MDs and PhDs
- Current programs with more than 150 biotech and pharmaceutical companies
- More than 2000 projects in process and completed
- In 2021, opened a new state-of-the-art research lab in Suzhou, China

